Tenofovir nephrotoxicity: Focusing research questions and putting them into clinical context

Journal of Infectious Diseases

Volumn 197, Issue 1, 2008, Pages 7-9

  Szczech, Lynda Anne ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL;

COHORT ANALYSIS; DRUG SAFETY; EDITORIAL; FANCONI RENOTUBULAR SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; NEPHROTOXICITY; POPULATION RISK; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; URINALYSIS;

ADENINE; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; KIDNEY TUBULES; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 39349108563     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/524091     Document Type: Editorial

References (16)

1. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40:1331-3.
2. Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002; 324:342-4.
3. Gaspar G, Monereo A, Garcia-Reyne A, de Guzman M. Fanconi syndrome and acute renal failure in a patient treated with tenofovir: a call for caution. AIDS 2004; 18:351-2.
4. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 2004; 35:269-73.
5. Schaaf B, Aries SP, Kramme E, Steinhoff J, Dalhoff K. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2003; 37:e41-3.
6. Murphy MD, O'Hearn M, Chou S. Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis 2003; 36:1082-5.
7. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36:1070-3.
8. Creput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003; 17:935-7.
9. Gilead Sciences. VIREAD (tenofovir disoproxil fumarate) tablets. Available at: http://www.gilead.com/pdf/viread_pi.pdf. Accessed 20 July 2007.
10. Goicoechea M, Lui S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008; 197:102-8 (in this issue).
11. Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1-infected patients: data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005; 20:743-6.
12. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
13. Szczech LA, Hoover D, Cai X, et al. The association between renal disease and outcomes among HIV-infected women taking and not taking antiretroviral therapy. Clin Infect Dis 2004; 39:1199-206.
14. Gardner LI, Klein RS, Szczech LA, et al. Rates and risk factors for overall and specific condition-associated hospitalizations in HIV-infected women. J Acquir Immune Defic Syndr 2003; 34:320-30.
15. Gardner LI, Holmberg SD, Williamson JM, et al. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:203-9.
16. Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, Klotman PE. Highly active antiretroviral therapy and the epidemic of HIV+ end-stage renal disease. J Am Soc Nephrol 2005; 16:2412-20.